This article was selected to be shared with PRO+ Small and Micro subscribers - find out more here.
Sirona Biochem (Ticker: OTCPK:SRBCF) is a nano/micro-cap company with a cosmetic and pharmaceutical program. Their proprietary fluorination platform for creating more stable carbohydrate-based drugs was what initially caught our interest. But drug development is a slow and expensive business. They currently only have one compound, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, for diabetes in their drug pipeline. This molecule is currently being developed by Wangbang/Fosun, a Chinese pharmaceutical company. The SGLT2 inhibitor program is looking